TD Cowen Raises Insulet (PODD) Price Target, Maintains Buy Rating

On June 4, TD Cowen has lifted its price target on Insulet Corporation (NASDAQ:PODD) to $379 from $324 while reiterating a Buy rating, pointing to strong early-year performance and recent executive changes that could reinforce the company’s momentum. The upward revision follows a standout first quarter and the appointment of Ashley McEvoy as chief executive in April.

TD Cowen Raises Insulet (PODD) Price Target, Maintains Buy Rating

A pharmacy worker placing wireless handheld personal diabetes managers against the light.

Insulet Corporation (NASDAQ:PODD)’s first-quarter results exceeded expectations, underscoring robust demand for its Omnipod insulin management system and continued traction in the Type 2 diabetes segment. TD Cowen noted that the performance reflects successful commercial execution and broader adoption across patient demographics. The firm views McEvoy’s arrival as a timely catalyst for sustained growth. With a background in medical technology and leadership experience at Johnson & Johnson, her appointment is seen as a strategic move that could enhance Insulet’s focus on scaling operations and sharpening its long-term vision.

McEvoy is expected to build on the company’s recent wins, particularly in expanding access and refining product innovation. Analysts believe her leadership will be instrumental in keeping up the pace in markets that are becoming increasingly competitive. TD Cowen emphasized that the company’s progress in the Type 2 diabetes space—an area with significant runway—is especially promising. The revised price target reflects confidence that both operational momentum and fresh executive perspective will continue to drive value through the remainder of the year and beyond.

While we acknowledge the potential of PODD as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than PODD and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 13 Cheap AI Stocks to Buy According to Analysts and 11 Unstoppable Growth Stocks to Invest in Now

Disclosure: None.